Mr. Commissiong is President, CEO and a member of the Board of Directors of Amarantus, the company he co-founded with John Commissiong, PhD in 2008. From the inception of the Company, Mr. Commissiong attracted seed capital, acquired the intellectual property rights to MANF and recruited scientific and executive talent to Amarantus to allow for the further development of the technologies. Prior to becoming CEO in October 2011, Mr. Commissiong was the Chief Operating Officer where his duties included strategic transactions, licensing, research collaborations, mergers and acquisitions, and fund raising. From August 2009 until March 2011, he served as Chief Business Officer where he was responsible for business and corporate development. Prior to co-founding Amarantus, Mr. Commissiong played professional football for the Calgary Stampeders of the Canadian Football League. Mr. Commissiong received a B.Sc. in Management Science and Engineering with a focus on Financial Decisions from Stanford University.

Recent Posts

Dr. Commissiong has served as the Chief Scientific Officer and a Director of Amarantus since co-founding the company in 2008. Prior to Amarantus, Dr. Commissiong served as the CSO of Neurotrophics, Inc. and  Prescient Neuropharma, Inc.  Throughout his distinguished career, Dr. Commissiong has been focused on the discovery of novel neurotrophic factors for the treatment of neurodegenerative diseases as well as understanding the fundamental underlying biology of protoplasmic type-1 astrocytes that secrete neurotrophic factors. He was Chief of the Neural Transplantation Unit, NINDS-NIH, from 1989-94 where his research focused on identifying therapeutic approaches to spinal cord injury. Dr. Commissiong was Head of the Neurotrophic Factors Group, NINDS-NIH, from 1994-97 where he focused on developing technologies to systematically identify novel neurotrophic factors with applications for specific Central Nervous System disorders. He co-founded Prescient Neuropharma in 1999, and discovered MANF in 2003. MANF is currently in preclinical development for the treatment of Parkinson’s disease. The work pioneered by Dr. Commissiong has led to significant advancements in the field of astrocyte-neuron biology. Dr. Commissiong believes that a fundamental understanding of astrocyte-neuron interactions in the Central Nervous System will lead to a new generation of therapies to treat brain-related disorders.

Dr. Commissiong did his Postdoctoral work in the Lab Preclin Pharmac, NIMH-NIH, concentrating on the application of quadrupole mass spectrometry in the analysis of neurotransmitters. He holds a Ph.D. in Neurophysiology from the University of Southampton, an M.Sc. in Biochemical Pharmacology from the University of Southampton, and a B.S. in Biology and Chemistry from the University of the West Indies.

Recent Posts

Fumihiko Urano, MD, PhD, is currently the Samuel E. Schechter Professor of Medicine and the Director of International Wolfram Syndrome Registry at Washington University School of Medicine (http://wolframsyndrome.dom.wustl.edu/). Following his residency in Anatomic and Clinical Pathology and his clinical and research training program in Pediatric Pathology/Genetics, he studied molecular endocrinology and endoplasmic reticulum (ER) biology at New York University Medical Center.

Recent Posts

Dr. Rubinfeld is a renowned expert in the field of drug development, and a co-founder of Amgen, one of the most successful companies in the history of the biotechnology industry. He brings more than 40 years of biopharmaceutical leadership experience to Amarantus’ Board of Directors. Dr. Rubinfeld is currently a Board member of Regenicin, Inc. and CytRx Corporation. Earlier in his career, he served 12 years at Bristol Myers, where in addition to developing Amoxicillin and Cephadroxil, he was instrumental in licensing their original anti-cancer line of products, including Mitomycin, Etoposide, and Bleomycin. Dr. Rubinfeld is also credited with making a major scientific and public health contribution to society by inventing the first ever synthetic biodegradable detergent. In 1980, Dr. Rubinfeld was one of four co-founders of Amgen, Inc. and served as its Chief of Operations, where one of his primary efforts was the prioritization of erythropoietin (EPO) in Amgen’s pipeline due to its initial commercialization pathway under the Orphan Drug Act. In 1984, Dr. Rubinfeld won the prestigious Common Wealth Award for Science and Invention, which was a testament to his prowess for achieving major inventions, represented by the numerous patents obtained during his distinguished career. In 1991 he co-founded SuperGen, Inc., where he served as President and Chief Executive Officer until 2003 and as a Board member until 2005. He has also served as an advisor or Board member to a number of companies including AVI BioPharma and Quark Pharmaceuticals. Dr. Rubinfeld received a B.S. degree in chemistry from C.C.N.Y. and M.A. and Ph.D. in chemistry from Columbia University.

Recent Posts

Dr. Gibran is a UW professor of surgery and director of the UW Medicine Regional Burn Center at Harborview Medical Center. After completing her medical degree and residency in surgery at Boston University, she completed a one-year fellowship at the Burn Center at Harborview, followed by a two-year National Institutes of Health Trauma Fellowship in the UW Department of Surgery. Dr. Gibran’s expertise is in burns, critical care and wound healing. Her research includes the role of nerves in wound repair; genetic influences on scarring and long-term functional outcomes following burn injuries.

Recent Posts

Paula Terese Trzepacz, M.D. is currently President and CEO of conXiome LLC, a biotech and biopharma consulting firm, and Clinical Professor of Psychiatry at both Indiana University School of Medicine and Tufts Medical School. In 1999 she joined Eli Lilly and company where she worked in Phases 2, 3 and 4 Neurosciences drug development either as an administrative or scientific leader. Dr. Terese Trzepacz has experience in clinical trial design and medical support of global and US submissions and other regulatory agency related work. Trained in psychosomatic medicine, geriatric psychiatry and neuropsychiatry, her focus has been on teaching, clinical care and research for patients with cognitive and neurodegenerative disorders (including dementias, delirium, traumatic brain injury, and ADHD) and the development of clinical tools, drugs and/or biomarkers for these conditions.

Recent Posts

The surgical career of Dr. David H. Ahrenholz at the University of Minnesota has spanned 41 years, first as a resident and most recently as an Associate Professor, mentoring residents and serving as Co-Director of the Burn Center at the affiliated Regions Hospital in St. Paul. He first used cultured epidermal cells to treat a burn patient in 1985 and his research interests have been related to critical burn care and skin replacement, as well as frostbite and necrotizing skin infections. He has served terms as Government Affairs Committee Chairman, Treasurer and as 2014-15 President of the American Burn Association, and remains active on the ABA Board of Trustees after retiring from clinical practice at the end of 2015.

Recent Posts

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts